Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.

Abstract

Safety assessment of drug metabolites in the development of pharmaceuticals was discussed in January 2007 at the kick-off meeting of a "Drug Evaluation Forum", with reference to the views of clinicians and other academic representatives. Safety evaluation of metabolites cannot readily be based on a single theoretical framework, and basically a case-by-case approach is called for. These evaluations should be performed precisely and an accurate profile secured taking into account adverse reactions that are unpredictable from the parent compound administered in clinical studies and any signs or symptoms that may be associated with the metabolites. In addition, elimination of scientifically meaningless metabolite safety assessment studies is essential for prompt supply of high-quality drugs to the medical frontline. Preparation of an outline concept paper would be useful for achievement of shared understanding of issues of this type. Collective viewpoints obtained in this fashion are also relevant to the discussion on the need for guidance, and given a degree of flexibility may also be helpful for drug development and, in turn, society at large.

Cite this paper

@article{Naito2007CurrentOS, title={Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.}, author={Shinsaku Naito and Shigeru Furuta and Takemi Yoshida and Mitsukazu Kitada and Osamu Fueki and Takashi Unno and Yasuo Ohno and Hiroshi Onodera and Nobuyuki Kawamura and Misao Kurokawa and Fumio Sagami and Kazutoshi Shinoda and Takahiro Nakazawa and Tsuneyoshi Yamazaki}, journal={The Journal of toxicological sciences}, year={2007}, volume={32 4}, pages={329-41} }